权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

the Gut Microbiome as a Disease Modifier of Heterotopic Ossification

肠道微生物组作为异位骨化的疾病调节剂

基本信息

批准号：
10624949
负责人：
EDWARD C HSIAO
金额：
$ 66.07万
依托单位：
EMORY UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-06-01 至 2027-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10624949
关键词：
ACVR1 gene Ablation Affect Anti-Inflammatory Agents Antibiotics Antigens Bacteria Biological Assay Blood Bone Marrow Cells Cessation of life Chemotaxis Chemotaxis Induction Circulation Clinical DNA Sequence Alteration Data Diet Dietary Factors Dietary Supplementation Disease Disease Outcome Disease Progression Environmental Risk Factor Flare Genetic Genetic Diseases Germ-Free Gnotobiotic Goals Heterotopic Ossification Home Human Human Microbiome Immobilization Immune In Vitro Infiltration Inflammation Inflammatory Inflammatory Response Injections Innate Immune System Intramuscular Joints Knowledge Life Macrophage Macrophage Activation Measures Methods Microfluidics Mus Muscle Musculoskeletal Diseases Mutation Myelogenous Orthopedic Surgery Osteogenesis Pain Patients Phase Phenotype Point Mutation Process Production Role Sampling Severities Siblings Signal Transduction Skeletal Muscle Symptoms System Testing Transplantation activin A bone morphogenetic protein receptors cell motility chemokine chronic pain cohort commensal microbes cytokine fecal microbiome fecal transplantation gut microbiome gut microbiota in vivo induced pluripotent stem cell microbial microbial community microbiome microbiota migration monocyte mouse model musculoskeletal injury non-genetic novel novel therapeutic intervention premature prevent probiotic supplementation progressive myositis ossificans receptor repaired response soft tissue stool sample systemic inflammatory response

项目摘要

Fibrodysplasia ossificans progressiva (FOP) is a currently untreatable genetic disease in which skeletal muscle repair is redirected to endochondral bone formation (heterotopic ossification, HO) causing pain, muscle destruction, and joint fusion, leading to progressive immobilization and eventually premature death. This project will explore the role of microbiota in inflammation and HO in FOP. Aim 1: Identify the modulatory roles of the gut microbiome in disease progression in FOP mice. Advanced gnotobiotic methods and germ-free FOP mice colonized with defined pro- or anti-inflammatory microbiota. We will also test whether dietary supplementation with probiotic bacteria or compounds that tighten gut barrier integrity will reduce FOP progression. Aim 2: Identify the role of the microbiome in chemokine-dependent polarization and migration of MCYs and macrophages that enhance EHO in FOP. These studies will determine whether the gut microbiome exacerbates EHO in FOP by sensitizing bone marrow MCYs/MΦs to chemokine-induced chemotaxis and increasing the expression of proinflammatory chemokines during flares, which together increase infiltration and inflammatory polarization of MCYs and MΦs. Aim 3: Establish the relationship between gut microbiota, monocyte/macrophage activation, and severity of FOP flares in humans and mice. These studies will determine if the gut microbial community in patients with FOP modulates disease progression by increasing systemic inflammatory tone, thus priming MCY/MΦ activation. Stool samples will be collected from patients with FOP, microbiota analyzed and correlated with FOP disease outcomes. We will also colonize germ-free FOP mice with the microbiome of human FOP patients by fecal transplant in a human microbiome-association (HMA) approach. Finally, we will use a new microfluidic culture system to determine the responses of human iPSC derived M1- and M2-like MΦs from control and FOP patients to defined microbiome antigens.These studies will provide novel mechanistic understanding of how the gut microbiome affects HO and provide a basis for testing how gut microbiome manipulation may augment treatment of FOP and non-genetic HO.

进行性骨化性纤维发育不良（FOP）是一种目前无法治疗的遗传病，骨骼肌